WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H318659
CAS#: 135062-02-1
Description: Repaglinide is an antidiabetic drug in the class of medications known as meglitinides, and was invented in 1983. Repaglinide is an oral medication used in addition to diet and exercise for blood sugar control in type 2 diabetes mellitus. The mechanism of action of repaglinide involves promoting insulin release from β-islet cells of the pancreas.
Hodoodo Cat#: H318659
Name: Repaglinide
CAS#: 135062-02-1
Chemical Formula: C27H36N2O4
Exact Mass: 452.27
Molecular Weight: 452.590
Elemental Analysis: C, 71.65; H, 8.02; N, 6.19; O, 14.14
Related CAS #: 147852-26-4
Synonym: Repaglinide; AG-EE 388 ZW; AG-EE388 ZW; AG-EE-388 ZW; AG-EE 623 ZW, AG-EE623 ZW, AG-EE-623 ZW, Prandin, GlucoNorm, Surepost, NovoNorm
IUPAC/Chemical Name: 2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid
InChi Key: FAEKWTJYAYMJKF-QHCPKHFHSA-N
InChi Code: InChI=1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1
SMILES Code: O=C(O)C1=CC=C(CC(N[C@H](C2=CC=CC=C2N3CCCCC3)CC(C)C)=O)C=C1OCC
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 452.59 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Yin J, Deng H, Qin S, Tang W, Zeng L, Zhou B. Comparison of repaglinide and metformin versus metformin alone for type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2014 Sep;105(3):e10-5. doi: 10.1016/j.diabres.2014.06.009. Epub 2014 Jun 23. Review. PubMed PMID: 25005849.
2: Khamaisi M. Severe hypoglycaemia from repaglinide-brotizolam drug interaction: a case report and literature review. Diabet Med. 2012 Sep;29(9):1214-5. doi: 10.1111/j.1464-5491.2012.03631.x. Review. PubMed PMID: 22414218.
3: Scott LJ. Repaglinide: a review of its use in type 2 diabetes mellitus. Drugs. 2012 Jan 22;72(2):249-72. doi: 10.2165/11207600-000000000-00000. Review. Erratum in: Drugs. 2012 Mar 26;72(5):744-5. PubMed PMID: 22268393.
4: Rawat MK, Jain A, Mishra A, Muthu MS, Singh S. Development of repaglinide loaded solid lipid nanocarrier: selection of fabrication method. Curr Drug Deliv. 2010 Jan;7(1):44-50. Review. PubMed PMID: 20044909.
5: Johansen OE, Birkeland KI. Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review. Am J Cardiovasc Drugs. 2007;7(5):319-35. Review. PubMed PMID: 17953471.
6: Plosker GL, Figgitt DP. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. Pharmacoeconomics. 2004;22(6):389-411. Review. PubMed PMID: 15099124.
7: [symbol: see text] Nateglinide and [symbol: see text] repaglinide for type 2 diabetes? Drug Ther Bull. 2003 Jul;41(7):52-4. Review. PubMed PMID: 12879789.
8: Matsuda M, Kaku K. [Repaglinide (NN-623)]. Nihon Rinsho. 2002 Sep;60 Suppl 9:555-8. Review. Japanese. PubMed PMID: 12387050.
9: Culy CR, Jarvis B. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. Drugs. 2001;61(11):1625-60. Review. PubMed PMID: 11577798.
10: Moses R. A review of clinical experience with the prandial glucose regulator, repaglinide, in the treatment of type 2 diabetes. Expert Opin Pharmacother. 2000 Dec;1(7):1455-67. Review. PubMed PMID: 11249478.
11: Moses R. Combination therapy in type 2 diabetes: the role of repaglinide. J Assoc Physicians India. 2001 Jan 25;49 Spec No:62-8. Review. PubMed PMID: 11235608.
12: Menon PS. Current understanding regarding the role of repaglinide in post-prandial hyperglycemia. J Assoc Physicians India. 2001 Jan 25;49 Spec No:50-3. Review. PubMed PMID: 11235606.
13: Owens DR, McDougall A. Repaglinide: prandial glucose regulation in clinical practice. Diabetes Obes Metab. 2000 Mar;2 Suppl 1:S43-8. Review. PubMed PMID: 11225759.
14: Massi-Benedetti M, Damsbo P. Pharmacology and clinical experience with repaglinide. Expert Opin Investig Drugs. 2000 Apr;9(4):885-98. Review. PubMed PMID: 11060717.
15: Schatz H. Preclinical and clinical studies on safety and tolerability of repaglinide. Exp Clin Endocrinol Diabetes. 1999;107 Suppl 4:S144-8. Review. PubMed PMID: 10522841.
16: Malaisse WJ. Repaglinide, a new oral antidiabetic agent: a review of recent preclinical studies. Eur J Clin Invest. 1999 Jun;29 Suppl 2:21-9. Review. PubMed PMID: 10383607.
17: Guay DR. Repaglinide, a novel, short-acting hypoglycemic agent for type 2 diabetes mellitus. Pharmacotherapy. 1998 Nov-Dec;18(6):1195-204. Review. PubMed PMID: 9855316.
18: Balfour JA, Faulds D. Repaglinide. Drugs Aging. 1998 Aug;13(2):173-80. Review. Erratum in: Drugs Aging 1999 Jul;15(1):28. PubMed PMID: 9739505.
19: Raskin P. Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes. Diabetes Obes Metab. 2008 Dec;10(12):1167-77. doi: 10.1111/j.1463-1326.2008.00907.x. Epub 2008 May 20. Review. PubMed PMID: 18494804.
20: Scheen AJ. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet. 2007;46(2):93-108. Review. PubMed PMID: 17253883.
